Group items matching

in title, tags, annotations or url

Target poorly membrane-permeable peptides Molecular weight: Approx. 500-2000 Technology requirements The Client seeks either one of the following types of technologies: (1) A formulation / DDS technology to deliver poorly membrane-permeable peptides into target cells Target sites / diseases: Not specified                        * Excludes technologies that are applicable only to cancer cells Routes of administration: Oral, intravenous, subcutaneous and intramuscular injections (delivered through blood vessels into target cells), transnasal (delivered from olfactory bulbs into brain tissues), transpulmonary (delivered into / retained in lung cells, for lung diseases), etc. (2) A formulation / DDS technology to enhance gastrointestinal absorption of poorly membrane-permeable peptides with both of para- and trans-cellular routes.

This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

The purpose of the FOA is to support the large scale molecular platform analysis of brain tissue, human biofluid or human induced pluripotent stem cell resources for the identification of targets and pathways associated with Alzheimer's Disease Related Dementias (ADRDs) pathophysiology.

The Simons Foundation Autism Research Initiative improves the understanding, diagnosis, and treatment of autism spectrum disorders by funding innovative research of the highest quality and relevance. To that end, SFARI is inviting applications for its SFARI Research Awards from individuals ready to conduct bold and rigorous research. The goal of the award is to provide support for investigation of key unresolved research questions in autism, particularly those that connect genetic etiologies to brain function and behavior. The program welcomes risk and novelty, but they are not required criteria for a proposal to be considered meritorious.

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. This includes technologies that do not rely on the use of human fetal tissue, as described in NOT-19-042. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

CIFAR invites exceptional early career researchers to join CIFAR's global network of 370 researchers from 18 countries who together are pursuing answers to some of the most complex challenges facing the world today. The CIFAR Azrieli Global Scholars program provides funding, skills training, mentorship, and opportunities to collaborate with outstanding colleagues from diverse disciplines to position scholars as leaders and agents of change within academia and beyond. CIFAR Azrieli Global Scholars receive: * $100,000 CDN in unrestricted research support * A two-year membership to a CIFAR research program, with outstanding research leaders from across disciplines. Learn what it's like to be a CIFAR Fellow * Specialized leadership and communication skills training Applicants can be from anywhere in the world, must hold a PhD (or equivalent) and be within the first five years of a full-time academic appointment. Please note that postdoctoral fellows are not eligible to apply to the program. Scholars' research interests must be aligned with the themes of an eligible CIFAR research program.  In 2018, the eligible programs are: * Azrieli Program in Brain, Mind & Consciousness * Bio-Inspired Solar Energy * Gravity & the Extreme Universe * Humans & the Microbiome * Molecular Architecture of Life

The Energy, Power, Control, and Networks (EPCN) Program supports innovative research in modeling, optimization, learning, adaptation, and control of networked multi-agent systems, higher-level decision making, and dynamic resource allocation, as well as risk management in the presence of uncertainty, sub-system failures, and stochastic disturbances. EPCN also invests in novel machine learning algorithms and analysis, adaptive dynamic programming, brain-like networked architectures performing real-time learning, and neuromorphic engineering. EPCN's goal is to encourage research on emerging technologies and applications including energy, transportation, robotics, and biomedical devices & systems. EPCN also emphasizes electric power systems, including generation, transmission, storage, and integration of renewable energy sources into the grid; power electronics and drives; battery management systems; hybrid and electric vehicles; and understanding of the interplay of power systems with associated regulatory & economic structures and with consumer behavior.

Applications will be accepted from academic investigators and small companies with lead candidate therapeutic agents that require early stage testing prior to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) study in humans to begin proving the scientific concept in humans. This award will support Phase 1 studies or pilot small- scale Phase 2a studies for repurposed drugs in normal individuals or individuals with preclinical or symptomatic Alzheimer's disease (i.e. early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. In addition, proposals may be considered that are POC to validate biological marker(s) of disease progression in a clinical trial environment. Any proposal must have a clear focus on Alzheimer's disease and related disorder and be translational in nature. All proposals should clearly and explicitly outline the measure to be investigated, the methods for study, and outcomes. Researchers from underrepresented groups are encouraged to apply.

The National Institute on Alcohol Abuse and Alcoholism intends to renew an initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for Research Resources -Cooperative Agreements (U24) to provide technical and scientific support to the research projects (U01) as part of the Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA). The objective of the NADIA consortium is to investigate persistent changes in complex brain function-behavior relationships following adolescent alcohol exposure.

The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. This FOA will use the NIH Research Project Grant (R01) award mechanism and runs in parallel with another FOA, PAR-20-NNN, which encourages applications under the R21 mechanism. Also listed under R21.

Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.

The Alzheimer's Drug Discovery Foundation, in partnership with the Association for Frontotemporal Degeneration, has issued a Request for Proposals designed to accelerate and support innovative drug discovery programs for FTD, a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain.

This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood.

This funding opportunity supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing.

Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.

Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.

The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.

PAF is particularly, but not exclusively, interested in the following areas of research: § Improved treatment including nutrition § Development of chelating compounds for PA toxicity § Risk factors for brain damage in PA § Risk factors for development of pancreatitis in PA § Risk factors for development of cardiomyopathy and/or arrhythmias in PA § Disease modifiers in PA § Development of new animal or cell/tissue-models for the study of PA

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-testing research to elucidate cellular and molecular mechanisms that underlie diffuse white matter disease and small vessel disease in the brain, the relationships between them, and how they may contribute to cognitive impairment and dementia.

This Funding Opportunity Announcement (FOA) invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.